VAT1L

Across TCGA pan-cancer cohorts, VAT1L mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated VAT1L data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher VAT1L mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated VAT1L expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and CCRCC are the cancer types where VAT1L mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	III,IV	0.992	0.572	.001	33	view →
COAD	DFS	Quartile	II,III,IV	1.000	0.874	.032	12	view →
CCRCC	OS	Median	III,IV	0.202	0.985	.007	10	view →
LUAD	DFS	Median	All	0.871	0.438	.021	2	view →
LSCC	DFS	Median	All	0.967	0.908	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

VAT1L–PDAC (OS)

Open the PDAC breakdown →